Yeast study in rare autoimmune disease terminated early
NCT ID NCT03800056
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to compare the types of Candida yeast found in patients with two forms of autoimmune polyendocrinopathy, a rare condition where the immune system attacks multiple glands. Researchers planned to collect samples from the mouth and urine of 7 participants to see how often different Candida strains appear. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
7 people
The number who actually took part.
- Started
-
Apr 2021
- Finished
-
Aug 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients will be included during their routine follow-up for adrenal insufficiency or hypoparathyroidism in the endocrinology department of the University Hospital of Lille, in adult or pediatric endocrinology.
- Ages
-
Up to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. For both of groups, inclusion criteria are : * children aged 0 to 17 years old with the consent of both parents, and men and women between the ages of 18 and 85. * a reasonable delay of 2 weeks after the resolution of an intercurrent infectious episode is to be observed. * assent of the patient after information adapted to his age and his degree of understanding. * informed, express and written consent of the patient or of each of the holders of parental authority. 2. Inclusion criteria specific to group 1: Patients with a APS type 1 whose molecular diagnosis (mutation of the AIRE gene) has been established in the diagnosis of the disease, regardless of their mycological status (history of mycosis) or the presence of antifungal treatment. 3. Inclusion criteria specific to group 2 : Patients with APS type 2: - with adrenal insufficiency for 50% of them. - a delay of two weeks after stopping antifungal or antibiotic treatment in patients is to be respected. Exclusion Criteria: * impossibility to receive informed information for adults, or impossibility to receive enlightened information for the holders of parental authority if minor subject * inability to participate in the entire study, refusal to sign the consent. * people in an emergency situation. * persons deprived of their liberty. * pregnant or lactating woman (pregnant women will be offered to participate in the study after delivery).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Autoimmune polyendocrine syndrome type 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hop Claude Huriez Chu Lille
Lille, 59037, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.